How many drugs treat Advanced Prostatic Carcinoma?

Drug Landscape tracks 10 marketed treatments for Advanced Prostatic Carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Advanced Prostatic Carcinoma?

Most recent: Estring — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/advanced-prostatic-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Advanced Prostatic Carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced Prostatic Carcinoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Advanced Prostatic Carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Firmagon	degarelix	Ferring	Gonadotropin Releasing Hormone Receptor Antagonist	Gonadotropin-releasing hormone receptor	2008-01-01
Trelstar	triptorelin	Verity	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	2000-01-01
Zoladex	GOSERELIN ACETATE	Tersera	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1989-01-01
Zoladex	goserelin	Tersera	Gonadotropin Releasing Hormone Receptor Agonist	pituitary gonadotropin secretion	1989-01-01
Leuprolide Acetate	leuprolide-acetate	Pfizer	leuprorelin	Gonadotropin-releasing hormone receptor	1985-01-01
Lupron	leuprorelin	Accord Healthcare S.L.U.	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Lupron	leuprolide	Accord Healthcare S.L.U.	Gonadotropin Releasing Hormone Receptor Agonist	Gonadotropin-releasing hormone receptor	1985-01-01
Depoestradiol	ESTRADIOL CYPIONATE	Pfizer	Estrogen	Estrogen receptor beta	1979-01-01
Estrace	ESTRADIOL	Pfizer	Estrogen	Estrogen receptor	1975-01-01
Delestrogen	ESTRADIOL VALERATE	Ph Health	Estrogen	Estrogen receptor	1954-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-11 — Estring · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 3 drugs in Advanced Prostatic Carcinoma
Accord Healthcare S.L.U. · 2 drugs in Advanced Prostatic Carcinoma
Tersera · 2 drugs in Advanced Prostatic Carcinoma
Ferring · 1 drug in Advanced Prostatic Carcinoma
Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 drug in Advanced Prostatic Carcinoma
Pfizer Inc. · 1 drug in Advanced Prostatic Carcinoma
Ph Health · 1 drug in Advanced Prostatic Carcinoma
Universitaire Ziekenhuizen KU Leuven · 1 drug in Advanced Prostatic Carcinoma
University of Michigan Rogel Cancer Center · 1 drug in Advanced Prostatic Carcinoma
· 1 drug in Advanced Prostatic Carcinoma
Verity · 1 drug in Advanced Prostatic Carcinoma
Astellas Pharma Europe Ltd. · 1 drug in Advanced Prostatic Carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced Prostatic Carcinoma:

Cite this brief

Drug Landscape (2026). Advanced Prostatic Carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-prostatic-carcinoma. Accessed 2026-06-10.

Advanced Prostatic Carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing